Skip to content
Open access

Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry

Maria Mercedes Santoro D. Spalletta V. Spagnuolo Chiara Paletti G. Marchegiani M. Bellocchi Riccardo Lolatto L. Carioti Adriana Cervo Antonio Di Biagio Marta Fiscon Emanuele Focà Roberta Gagliardini Stefano Rusconi Maurizio Zazzi A. Castagna Francesco Saladini Francesca Ceccherini Silberstein Antonella Castagna V. Spagnuolo Daniele Armenia Stefano Bonora Leonardo Calza Anna Maria Cattelan Giovanni Cenderello Adriana Cervo Laura Comi Antonio Di Biagio Emanuele Focà Roberta Gagliardini A. Giacomelli Filippo Lagi G. Marchetti Stefano Rusconi Francesco Saladini Maria Santoro Maurizio Zazzi Andrea Galli BioRep Srl Elisabetta Carini Sabrina Bagaglio Girolamo Piromalli Riccardo Lolatto Nicolò Capra Marcello Riccardo Tavio Alessandra Mataloni Paggi Silvia Magnani Manuela Colafigli Ornella Schioppa Stefania Zanussi Valentina Da Ros Silvia Rossetto Annalisa Saracino Flavia Balena Daniela Valenti Pierluigi Viale Maddalena Giglia Claudio Rigamonti Silvia Cretella Francesco Castelli Davide Minisci Stefano Rapino Barbara Menzaghi Maddalena Farinazzo Chiara Abeli Bruno Cacopardo Maurizio Celesia Michele Salvatore Paternò Raddusa Carmen Giarratana Paolo Fusco Vincenzo Olivadese Simona Mongiardi Angelo Pan Chiara Fornabaio Paola Brambilla A. Bartoloni Paola Corsi Sasha Trevisan Giuseppe Gasparro C. Costa Alessio Bellucci Elisa Mariabelli Teresa Santantonio Sergio Lo Caputo Sergio Ferrara Arianna Narducci Emanuele Pontali Marcello Feasi Antonio Sarà Matteo Bassetti Sabrina Blanchi Stefania Piconi Martina Bottanelli Silvia Pontiggia Giada Valsecchi Cinzia Roberta Bassoli Francesco Bassani Liana Bevilacqua Rebecka Papaioannu Tommaso Clemente C. Muccini Golnaz Torkjazi S. Antinori Tiziana Formenti Giacomo Pozza L. Gazzola Fabiana Trionfo Fineo Massimo Puoti Cristina Moioli Federico D'Amico Elena Simoncini Serena Sassi Cristina Mussini Giulia Nardini Elio Manzillo Antonella Gallicchio Antonio Cascio Marcello Trizzino Elisa Fronti Diletta Laccabue Federica Carli Roberto Gulminetti Layla Pagnucco Mattia Demitri A. Ferrari Daniela Francisci Giuseppe De Socio Elisabetta Schiaroli Elisa Garlassi Romina Corsini Marisa Fusto L. Sarmati Vincenzo Malagnino Tiziana Mulas Mirko Compagno Carlo Torti Simona Di Giambenedetto Silvia Lamonica Pierluigi Salvo Rachele Pincino Davide Laurenda Giordano Madeddu Andrea De Vito Mario Tumbarello Massimiliano Fabbiani Francesca Panza Ilaria Rancan Giovanni Di Perri M. Ferrara A. Calcagno Silvia Fantino Giancarlo Orofino Guido Calleri Marta Guastavigna Stefano Nardi Marta Fiscon
Oct 2026 · Journal of Antimicrobial Chemotherapy · Vol 81 · 0 citations · 20 references
Medicine

Abstract

Abstract Background Lenacapavir (LEN) is a first-in-class, long-acting HIV-1 capsid inhibitor, approved for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multidrug resistance (MDR). To date, few data are available on resistance profiles in real life. Methods Paired plasma and PBMC samples from nine HTE PWH with MDR enrolled in the PRESTIGIO Registry receiving LEN in combination with an optimized background regimen were collected before (baseline) and during LEN treatment. Next-generation sequencing was performed using in-house protocols. LEN susceptibility was assessed by single-cycle assay. Intra-patient viral evolution was evaluated through quasispecies distance analysis. Results At baseline, no major LEN resistance-associated mutations were detected; the accessory capsid polymorphism T107A was identified as a minority variant (5.9%) in one case, with phenotypic assays confirming full LEN susceptibility (mean fold-change: 1.2). Participants received LEN for a median [IQR] of 19.8 [18.5–23.2] months. Two individuals started LEN with undetectable viremia and maintained suppression. The other seven participants were viremic; six achieved viral suppression, with one experiencing a blip. One low-adherent participant exhibited persistent viremia with Q67K and K70H as the majority variants in both plasma (98.5%; 97.8%) and PBMCs (75.7%; 75.6%), conferring a 2081-fold reduction in LEN susceptibility. Intra-host variability in the capsid and pol regions remained low over time and across compartments. Conclusions In this case series of HTE PWH with MDR, LEN was highly associated with maintenance or achievement of virological suppression and limited virus evolution, with only one participant remaining viremic and showing a majority highly LEN-resistant variant.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.